Skip to content
OpenCapital
Get started

Bio-Rad Laboratories BIO Cumulative Gross Losses and Impairments

Cumulative Gross Losses and Impairments at other companies

Zoetis logo
ZoetisZTS
——

Segments

By segment

See full
Clinical Diagnostics$293.4M0.0%
Life Science$41.8M0.0%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×—
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairedAccumulatedImpairmentLoss.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories's cumulative gross losses and impairments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories's cumulative gross losses and impairments?
Bio-Rad Laboratories (BIO) reported cumulative gross losses and impairments of $335.2M in Q1 2026.
How has Bio-Rad Laboratories's cumulative gross losses and impairments changed year-over-year?
Bio-Rad Laboratories's cumulative gross losses and impairments decreased by 0.0% year-over-year, from $335.2M to $335.2M.
What is the long-term trend for Bio-Rad Laboratories's cumulative gross losses and impairments?
Over 5 years (2020 to 2025), Bio-Rad Laboratories's cumulative gross losses and impairments has grown at a 0.0% compound annual growth rate (CAGR), from $335.2M to $335.2M.
What does cumulative gross losses and impairments mean?
This metric aggregates all unrealized losses and recognized impairment charges on investment securities that have not yet been realized through a sale. It provides a comprehensive view of the negative valuation adjustments impacting the bank's equity. It is a key indicator of the credit and market risk embedded in the bank's long-term holdings.